New pyrimido[5,4-b]indoles as ligands for α1-adrenoceptor subtypes

Journal of Medicinal Chemistry

Volumn 46, Issue 14, 2003, Pages 2877-2894

  Romeo, Giuseppe ^a   Materia, Luisa ^a   Manetti, Fabrizio ^d   Cagnotto, Alfredo ^c   Mennini, Tiziana ^c   Nicoletti, Ferdinando ^b   Botta, Maurizio ^d   Russo, Filippo ^a   Minneman, Kenneth P ^e  

^a UNIVERSITY OF CATANIA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 2 [4 BENZYLOXYCARBONYL 3 [(TERT BUTYLAMINO)CARBONYL] 1 PIPERAZINYL] 6,7 DIMETHOXYQUINAZOLINE; 5H PYRIMIDO[5,4 B]INDOLE (1H,3H) 2,4 DIONE; 7 CHLORO 3,4,5,6 TETRAHYDRO 4 METHYL 2 VINYLTHIENO[4,3,2 EF][3]BENZAZEPINE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; ALPHA 1 ADRENERGIC RECEPTOR; CYCLAZOCINE; DISCRETAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOXAZOSIN; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PRAZOSIN; PYRIMIDO[5,4 B]INDOLE DERIVATIVE; RN 5; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; SNAP 8719; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; PHARMACOPHORE; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; CELL LINE; COMPUTER SIMULATION; HUMANS; INDOLES; LIGANDS; MALE; MODELS, MOLECULAR; PYRIMIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0038798621     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0307741     Document Type: Article

References (56)

1. Graham, R. M.; Perez, D. M.; Hwa, J.; Piascik, M. T.; Alpha1-adrenergic receptor subtypes. Molecular structure, function, and signaling. Circ. Res. 1996, 78, 737-749.
2. Hieble, J. P.; Bylund, D. B.; Clarke, D. E.; Eikenburg, D. C.; Langer, S. Z.; Lefkowitz, R. J.; Minneman, K. P.; Ruffolo, R. R., Jr. International Union of Pharmacology. X. Recommendation for nomenclature of alpha1-adrenoceptors: consensus update. Pharmacol. Rev. 1995, 47, 267-270.
3. Ramarao, C. S.; Denker, J. M.; Perez, D. M.; Gaivin, R. J.; Riek, R. P.; Graham, R. M.; Genomic organization and expression of the human alpha 1B-adrenergic receptor. J. Biol. Chem. 1992, 267, 21936-21945.
4. Hirasawa, A.; Horie, K.; Tanaka, T.; Takagaki, K.; Murai, M.; Yano, J.; Tsujimoto, G. Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor. Biochem. Biophys. Res. Commun. 1993, 195, 902-909.
5. 1D-adrenergic receptor and inducible expression of three human subtypes in SKNMC cells. Mol. Pharmacol. 1995, 47, 591-598.
6. Price, D. T.; Lefkowitz, R. J.; Caron, M. G.; Berkowitz, D.; Schwinn, D. A. Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues; implication for human alpha-adrenergic physiology. Mol. Pharmacol. 1994, 45, 171-175.
7. 1A-adrenoceptor isoforms. FEBS Lett. 1998, 422, 279-283.
8. 1A-adrenoceptors. Biochem. J. 1999, 343, 231-239.
9. Timmermans, B. M. W. M.; van Zwieten, P. A. α-Adrenoceptor agonists and antagonists. Drugs Future 1984, 9, 41-55.
10. Holmes, J. B.; Christensen, M. M.; Rasmussen, P. C.; Jacobsen, F.; Nielsen, J.; Norgaard, J. P.; Olesen, S.; Noev, I.; Wolf, H.; Husted, S. E. 29-Week doxazosin treatment in patients with symptomatic benign prostatic hyperplasia. Scand. J. Urol. Nephrol. 1994, 28, 77-82.
11. Forray, C.; Bard, J. A.; Wetzel, J. M.; Chiu, G.; Shapiro, E.; Tang, R.; Lepor, H.; Hartig, P. R.; Weinshank, R. L.; Branchek, T. A. The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned alpha 1c subtype. Mol. Pharmacol. 1994, 45, 703-708.
12. 1-AR subtypes in human hypertrophied prostate by in situ hybridization. Histochem. J. 1996, 28, 283-288.
13. 1-Adrenoceptor antagonist. Drugs Future 2001, 26, 553-550.
14. 1A-adrenoceptor selective antagonists for the treatment of benign prostatic hyperplasia. Drugs Future 2001, 26, 757-765.
15. Stam, W. B.; Van der Graaf, P. N.; Saxena, P. R. Functional characterization of the pharmacological profile of the putative alpha1B-adrenoceptor antagonist, (+)-cyclazosin. Eur. J. Pharmacol. 1998, 361, 79-83.
16. Giardinà, D.; Crucianelli, M.; Romanelli, R.; Leonardi, A.; Poggesi, E.; Melchiorre, C. Synthesis and biological profile of the enantiomers of [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)cis-octahydroquinoxalin-1-yl] furan-2-ylmethanone (Cyclazosin), a potent competitive α1B- adrenoceptor antagonist. J. Med. Chem. 1996, 39, 4602-4607.
17. 1b adrenergic antagonist. J. Med. Chem. 1998, 41, 1205-1208.
18. 1-adrenoceptor. Eur. J. Pharmacol. 1995, 272, R5-R6.
19. 1A receptor in rat and guinea pig hippocampal membranes. Eur. J. Pharmacol. 1987, 137, 293-294.
20. 1-adrenoceptor ligands. J. Med. Chem. 1991, 34, 1850-1854.
21. 1-adrenoceptors. Farmaco 1995, 50, 471-477.
22. 1-adrenoceptor subtypes. J. Heterocycl. Chem. 2001, 38, 391-395.
23. Unangst, P. C. Pyrimido[1′,2′:1,2]pyrimido[5,4-b)indoles. A new heterocyclic ring system. J. Heterocycl. Chem. 1983, 20, 495-499.
24. Parcell, R. F. 4-(o-Substitutedphenyl)-1-hydroxyalkylpiperidines. U.S. Patent 2,891,066, 1959.
25. 1A receptor. Eur. J. Med. Chem. 1993, 24, 499-504.
26. Gupta, S. P.; Chatterjee, S. S.; Bindra, J. S.; Jain, P. C.; Anand, N. Compounds acting on CNS: Part XXII - Synthesis of 2,3,4,4a,5,6-hexahydro-1(H)-pyrazino[2,1-c]-1,4-benzoxazines. Indian J. Chem. 1975, 13, 462-467.
27. 1A receptor. U.S. Patent 5,512,566, April 30, 1996.
28. 1A receptors. Bioorg. Med. Chem. Lett. 1997, 7, 763-768.
29. Predvoditeleva, G. S.; Shchukina, M. N. Synthesis of benzomorpholine derivatives. I. Zh. Obshch. Khim. 1963, 33, 145-150; Chem. Abstr. 1963, 59, 609a.
30. Predvoditeleva, G. S.; Shchukina, M. N. Synthesis of benzomorpholine derivatives. I. Zh. Obshch. Khim. 1963, 33, 145-150; Chem. Abstr. 1963, 59, 609a.
31. 1 oxidant for the conversion of primary and secondary alcohols to aldehydes and ketones. J. Org. Chem. 1983, 48, 4155-4156.
32. Geiss, W. B. Technical Report; Albany Molecular Research, Inc.: Albany, NY, 1999; Vol. 1, Issue 11.
33. 1-Adrenoceptor. Eur. J. Pharmacol. 2002, 453 (2, 3), 231-238.
34. 1-Adrenergic Receptor Subtypes: Titration of Receptor Density and Responsiveness with Inducible and Repressible Expression Vectors. Mol. Pharmacol. 1996, 50, 1376-1387.
35. Barbaro, R.; Betti, L.; Botta, M.; Corelli, F.; Giannaccini, G.; Maccari, L.; Manetti, F.; Strappaghetti, G.; Corsano, S. Synthesis, biological evaluation, and pharmacophore generation of new pyridazinone derivatives with affinity toward α1- and α2-adrenoceptors. J. Med. Chem. 2001, 44, 2118-2132.
36. Catalyst, version 4.6; Accelerys, Inc.: San Diego, CA, 2000.
37. De Marinis, R. M.; Wise, M.; Hieble, J. P.; Ruffolo, R. R., Jr. Structure-Activity Relationships for Alpha-1 Adrenergic Receptor Agonists and Antagonists. In The Alpha-1 Adrenergic Receptor; Ruffolo, R. R., Jr., Ed.; Humana Press: Clifton, NJ, 1987; pp 211-265.
38. 1-Adrenoceptor Selective Antagonists: Synthesis, Modeling, and Binding Studies. Bioorg. Med. Chem. 1998, 6, 925-935.
39. 1 Adrenoceptor Subtype Selective Antagonists. Bioorg. Med. Chem. 2000, 8, 201-214.
40. Konkel, M. J.; Wetzel, J. M.; Cahir, M.; Craig, D.; Noble, S. A.; Gluchowski, C. Discovery of Antagonists Selective for the Alpha1D-Adrenoceptor. Presented at the 216th National Meeting of the American Chemical Society, Boston, August 23-27, 1998; Paper MEDI 129.
41. (a) Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMm: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187, 217.
42. (b) Catalyst force field and potential energy functions are described in the file REFenergy.doc.html provided by Accelerys along with the program Catalyst 4.6.
43. (a) Smellie, A.; Teig, S. L.; Towbin, P. Poling: Promoting Conformational Coverage. J. Comput. Chem. 1995, 16, 171-187.
44. (b) Smellie, A.; Kahn, S. D.; Teig, S. L. An Analysis of Conformational Coverage 1. Validation and Estimation of Coverage. J. Chem. Inf. Comput. Sci. 1995, 35, 285-294.
45. (c) Smellie, A.; Kahn, S. D.; Teig, S. L. An Analysis of Conformational Coverage 2. Applications of Conformational Models. J. Chem. Inf. Comput. Sci. 1995, 35, 295-304.
46. 1-Adrenoceptor Antagonists. Rational Design, Synthesis and Biological Evaluation of New Trazodone-like Compounds. Bioorg. Med. Chem. Lett. 2002, 12, 437-440.
47. 1-Adrenoceptor Antagonists. Bioorg. Med. Chem. 2002, 10, 361-369.
48. 1d-adrenergic receptor activation: a molecular dynamics and docking study. Proteins 2001, 43, 382-394.
49. Kenny, B.; Ballard, S.; Blagg, J.; Fox, D. Pharmacological options in the treatment of benign prostatic hyperplasia. J. Med. Chem. 1997, 40, 1293-1315.
50. Ruffolo, R. R., Jr.; Bondinell, W.; Ku, T.; Naselsky, D. P.; Hieble, J. P. Alpha1-adrenoceptors: pharmacological classification and newer therapeutic applications. Proc. West. Pharmacol. Soc. 1995, 38, 121-126.
51. Minneman, K. P.; Theroux, T. L.; Hollinger, S.; Han, C.; Esbenshade, T. A. Selectivity of agonist for cloned alpha1-adrenergic receptor subtypes. Mol. Pharmacol. 1994, 46, 929-936.
52. GraphPad Prism; GraphPad Software Inc., San Diego, CA, 2000.
53. Caccia, S.; Confalonieri, S.; Guiso, G.; Bernasconi, P.; Cagnotto, A.; Skorupska, M.; Mennini, T. Brain uptake and distribution of the potential memory enhancer CL 275,838 and its main metabolites in rats: relationship between brain concentrations and in vitro potencies on neurotransmitter mechanisms. Psychopharmacology 1994, 115, 502-508.
54. Allfit; National Institutes of Health: Bethesda, MD, 1988.
55. 50) of an enzymatic reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
56. 1-adrenoceptors. Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 1931-1935.